More importantly, this hypoxic-driven angiogenesis will further support treatment-resistant GSCs in the heterogeneous GBM tumor and promote an influx of CD11b+ and CD68+ immunosuppressive myeloid cells [197], conferring a more invasive phenotype. This evidence concerns the gene ITGAM and neoplasm.